


Cite this: *Nanoscale*, 2023, **15**, 10057

# Label-free detection of MiRNA biomarkers using broadband multi-resonant infrared metasurfaces for early breast cancer diagnosis†

Shuyan Zhang,<sup>a</sup> Qing Yang Steve Wu,<sup>a</sup> Yi Fan Chen,<sup>a</sup> Melissa Hum,<sup>b</sup> Dave Chi Lok Wong,<sup>c</sup> Ern Yu Tan,<sup>d,e</sup> Ann Siew Gek Lee,<sup>\*b</sup> Jinghua Teng,<sup>ID</sup> <sup>\*a</sup> Dinish U.S.<sup>\*a</sup> and Malini Olivo<sup>\*a</sup>

Breast cancer is the most prevalent cancer globally. Early detection is crucial and can be achieved by detecting cancer biomarkers in blood, such as circulating miRNAs (microRNAs). In this study, we present a label-free detection method based on broadband multi-resonant infrared metasurface for surface-enhanced infrared absorption (SEIRA) spectroscopy to detect miRNAs. The SEIRA resonances were optimized to match the miRNA biomarker fingerprint regions in the range of 800 to 2000 cm<sup>-1</sup> and 2800 to 3500 cm<sup>-1</sup>, resulting in a simulated resonance enhancement of up to 10<sup>3</sup> times. Nine patient samples (six cancerous and three non-cancerous) were measured using SEIRA multi-well sensor chips. A novel analysis method, SEIRA-AR, was also developed to benchmark the results against industry standards, such as quantitative reverse transcription polymerase chain reaction (RT-qPCR) and next-generation sequencing (NGS). Our results showed an excellent linear correlation with a Pearson's *r* value of up to 0.99 and an *R* Squared value of up to 0.98. This study represents the first use of a SEIRA sensor for biomarker detection on clinical breast cancer samples and introduces an analysis method that produces results comparable to industry standards. Our findings pave the way for routine cancer diagnosis in the future. Additionally, the method discussed can be generalized to other biosensing activities involving two-step binding processes with complementary molecule-capturing agents.

Received 24th March 2023,

Accepted 18th May 2023

DOI: 10.1039/d3nr01369c

rsc.li/nanoscale

## Introduction

Breast cancer is the most commonly diagnosed cancer globally, with about 2.3 million newly diagnosed cases and 685 000 deaths in 2020.<sup>1</sup> The current approach for screening breast cancer in asymptomatic individuals is mammography. Although mammography is deemed the gold standard for

breast cancer screening, it has many well-recognized shortcomings, such as high false-positive results, overdiagnosis, and poor participation rates.<sup>2,3</sup> False-positive mammograms are also more common among younger women or women of Asian ethnicities due to the presence of denser breast tissue, affecting the sensitivity and specificity of mammography.<sup>4,5</sup> A study in the U.S. has shown that 11–13% of all screening mammograms are abnormal, with true-positive rates standing below 0.5% of all screening mammograms. Hence, a person with an abnormal mammogram has a ~96% chance of having a false-positive result.<sup>6</sup> Furthermore, women with false-positive mammograms are subjected to unnecessary additional diagnostic imaging tests and tissue biopsies, which are stressful, invasive, expensive, and laborious. In addition, it has been reported that the national cost of false-positive mammograms and breast cancer overdiagnoses is \$4 billion annually, based on a study conducted in 2015.<sup>6</sup> Hence, there is a need for a less-invasive, quick, and reliable test to discriminate breast cancers and non-breast cancers in women with abnormal screening mammograms.

Various blood-based biomarkers have been reviewed for the early detection of breast cancer.<sup>7</sup> Circulating microRNAs

<sup>a</sup>Institute of Materials Research and Engineering (IMRE), Agency for Science, Technology and Research (A\*STAR), 2 Fusionopolis Way, Innovis #08-03, Singapore, 138634, Republic of Singapore. E-mail: dinish@imre.a-star.edu.sg, malini\_olivo@imre.a-star.edu.sg, jh-teng@imre.a-star.edu.sg

<sup>b</sup>Division of Cellular and Molecular Research, Humphrey Oei Institute of Cancer Research, National Cancer Centre (NCC), 30 Hospital Boulevard, Singapore, 169610, Republic of Singapore. E-mail: dmslsg@nccs.com.sg

<sup>c</sup>Chang Gung University, No. 259, Wenhua 1 st Rd, Guishan District, Taoyuan City, 333 Taiwan, Republic of China

<sup>d</sup>Breast & Endocrine Surgery, Tan Tock Seng Hospital (TTSH), 11 Jln Tan Tock Seng, Singapore, 308433, Republic of Singapore

<sup>e</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, 50 Nanyang Avenue, Singapore, 639798, Republic of Singapore

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3nr01369c>



(miRNAs) have emerged as a promising non-invasive biomarker for cancer diagnosis and prognosis because of their remarkable stability in the bloodstream and their involvement in cancer development and progression.<sup>8,9</sup> They are a class of small non-coding RNAs with 19 to 25 nucleotides that play important roles in regulating gene expression. Conventional methods such as northern blotting, microarray-based hybridization, quantitative reverse transcription polymerase chain reaction (RT-qPCR), and next-generation sequencing (NGS) have been widely used to detect miRNAs.<sup>10</sup> However, some of these methods are costly, and they involve complex and time-consuming procedures. Hence, we propose an alternative label-free approach based on surface-enhanced infrared absorption (SEIRA) to measure the target miRNA molecule contents in total RNA solutions extracted from the patient's blood serum samples. The infrared spectroscopy technique detects the molecular vibrations that result in a change of the dipole moment of the molecules, and it measures the absolute frequency (molecular fingerprints) where the molecules absorb infrared light in a label-free manner. SEIRA is a technique based on the resonant effect of the metasurface nanostructures at the substrate surface, where the molecules interact with the incident light to improve the sensitivity of infrared spectroscopy measurements.<sup>11,12</sup> The resonance wavelength(s) can be tuned by the material, shape, and size of the nanostructures. Many nanostructures have been proposed, including zig-zag nanotips, nanorods, nanodiscs, nanoislands, etc.<sup>13–21</sup>

Here, we demonstrate a multi-well SEIRA sensor chip based on metallic nanorod structures featuring a broad-band multi-band resonance. The structures are specifically designed so that the resonances coincide with the absorption fingerprint regions of the target miRNA biomarkers, hence maximizing the light interaction with the biomarker molecules and collected SEIRA signals. In addition, we demonstrate the possibility of multiplexed detection. The sensor chip comprises 15 millimeter-sized sensor wells capable of measuring multiple biomarkers and patient samples on a single platform. The SEIRA sensor structures are repeated in each well, and each well is isolated from its neighbors so that it can be treated as a separate SEIRA measurement site. We have earlier performed extensive studies on establishing a miRNA biomarker panel for early breast cancer diagnosis.<sup>22–24</sup> Here, we detected miRNAs hsa-miR-let-7a-5p, hsa-miR-451a, hsa-miR126-5p, and hsa-miR-195-5p, for patients who were clinically diagnosed with breast cancer by mammography and histopathology. The detection process involves binding thiol group-modified complementary single-stranded DNA (ssDNA) molecules to the SEIRA sensor and subsequent selective binding of target miRNA molecules to the complementary ssDNA molecules. We then propose to use the area ratio of the change in the area under the curve of the SEIRA signal at each step to represent the concentration of miRNAs in the sample. The analysis method is termed "SEIRAAR". It takes into account both the shift in the absorption peak position and the change in the intensity values across the entire infrared

absorption spectrum. An excellent correlation has been established between the SEIRA-AR index values and the industry-standard RT-qPCR and NGS read counts. This demonstrates that our proposed approach could accurately detect specific target miRNA molecules in a mixed environment. Moreover, our approach is label-free without the need to use fluorescent dyes, and it is relatively fast. It is one of the first successful demonstrations of a SEIRA sensor being used for biomarker detection in a clinical setting and compared with industry standards. The study paves the way for routine cancer diagnosis in the future. It can also be used for real-time and *in situ* label-free measurements of any biomarker, which can be captured and immobilized using a complementary targeting moiety.

## Materials and methodology

### Breast cancer sample preparation

The authors extracted the microRNAs from serum samples, which were prepared from the collected blood samples. Peripheral blood samples were collected at the National Cancer Centre Singapore (Singapore) and Tan Tock Seng Hospital (Singapore) prior to biopsy or surgery. Serum samples were also obtained from the SingHealth Tissue Repository (Singapore). The materials were not purchased/donated. There were five women with invasive breast carcinomas, one with ductal carcinoma *in situ* (DCIS), and three with benign fibroadenoma. Women with invasive carcinomas or DCIS were defined as cancerous cases, and others were non-cancerous (control) cases. This study was conducted in accordance with the Declaration of Helsinki, and approved by the Centralized Institutional Review Board of SingHealth (CIRB Ref: 2018/2874). Written informed consent was obtained from all study participants.

Total RNA was isolated from 200  $\mu$ l of serum using the miRNeasy Serum/Plasma Advanced Kit (Qiagen N. V.). This was performed according to the manufacturer's protocol, except for an additional step where bacteriophage MS2 RNA was added into the sample lysis buffer (1  $\mu$ g mL<sup>-1</sup> of QIAzol) to improve the RNA yield.

### SEIRA sensor fabrication

The SEIRA sensor consists of rod-shaped nanostructures fabricated using electron beam lithography (ELS-7000, Elionix Inc.). In this process, two layers of photoresists were spin-coated (PMMA 495 A3, 1 : 1 with IPA, 4000 rpm 90 seconds and hot plate cured at 180 °C for 10 minutes, followed by PMMA 950 A5, 1 : 2 with IPA, 4000 rpm 90 seconds and hot plate cured at 180 °C for 10 minutes) on a clean CaF<sub>2</sub> substrate. The electron beam current setting was 500 pA, 100 kV, and dosage 0.6. After the electron beam exposure, the sample was dipped into MIBK : IPA 1 : 3 solution for 1 minute, followed by rinsing and N<sub>2</sub> air gun drying. Electron beam evaporation (Explorer, Denton Vacuum) was performed subsequently to deposit 10 nm of Cr adhesion layer and 100 nm of Au layer. Lift off



process was then carried out using acetone solution to remove the extra film of PMMA, followed by washing in the IPA solution and DI water and then drying.

### Multi-well SEIRA sensor chip

Fig. 1(a) shows a multi-well sensor chip consisting of 5 rows and 3 columns with a total of 15 individual wells. Firstly, the SEIRA sensor structures were repeated 15 times, each with a dimension of  $500\ \mu\text{m} \times 500\ \mu\text{m}$  and a center-to-center distance of 7.5 mm. Next, a multi-well mask was created by a polydimethylsiloxane (PDMS) layer of thickness 1 mm with the well positions aligned with the patterned SEIRA structures. Each well was made by a pen puncher with a tip size of 1.5 mm. The PDMS layer was then placed on top of the SEIRA structures and adhered to by van der Waals force. The final sensor chip allows detection at multiple sites to be performed independently. The spacing between the cells ensures that the solutions will not cross over to neighboring wells. The size of each well ensures that SEIRA reflectance signals are collected with a reasonable sample area. For one of the experiments, we have arranged the wells so that the rows measure different patients (*i.e.*, patient sample 1–5) and the columns measure different target miRNA types (*i.e.*, miRNA 1–3). Finally, a micropipette was used to dispense the sample solutions precisely.

Fig. 1(b) is a schematic of the Fourier transform infrared (FTIR) system attached with a microscope accessory (Vertex 80v with Hyperion 2000, Bruker Corporation). A  $15\times$  reflective microscope objective was used to focus the incident light onto the SEIRA structure and collect the reflected signal. A region of interest of  $100\ \mu\text{m} \times 100\ \mu\text{m}$  was selected for each measurement. Three measurements were performed at different locations for each SEIRA structure to minimize the effect of fabrication non-uniformity and ensure measurement repeat-

ability. Each FTIR measurement was taken at the wavenumber range of  $800\text{--}5000\ \text{cm}^{-1}$  with a resolution of  $4\ \text{cm}^{-1}$  and 64 scans.

### Design of experiments

There were four experiments performed. The first was a baseline measurement using synthetic thiol group-modified ssDNA and miRNA samples (Integrated DNA Technologies, Inc.). The measurements were performed using an FTIR spectroscopy instrument with the attenuated total reflection (ATR) accessory (VERTEX 70v, Bruker Corporation) under the vacuum condition. The results were used to guide the SEIRA sensor nanostructures design and simulation. After the SEIRA sensor was designed and fabricated, the second to fourth experiments were conducted using the FTIR microscope system, as shown in Fig. 1(b). The second experiment was to quantify the SEIRA enhancement by comparing the measured FTIR signal of a bare area (without SEIRA structures) and with SEIRA structures. The third experiment sought to validate the proposed SEIRA-AR analysis method with both RT-qPCR and NGS results by measuring the miRNA concentration in five clinical samples. Finally, the fourth experiment demonstrated the capability of using the SEIRA sensor for multiplexed detection by measuring three breast cancer miRNA biomarkers from another set of five clinical samples and establishing a linear relationship between SEIRA-AR index values and RT-qPCR results.

The experimental workflow using the SEIRA sensor is as follows. Firstly, FTIR signals were collected from a clean SEIRA sensor. Fig. 2(a) shows a zoom-in view of the rod-shaped nanostructures of the SEIRA sensor with the dashed square highlighting the design unit cell. Secondly, solutions containing thiol group-modified complementary ssDNA molecules ( $2\ \mu\text{L}$ ,



**Fig. 1** Multi-well sensor chip design and measurement setup. (a) A schematic showing a sensor chip with 15 wells consisting of 5 rows and 3 columns. Each well can carry out an independent measurement. For example, rows can be used to measure different patients, and columns can be used to measure different target miRNAs. It consists of a bottom layer of SEIRA structure and a top layer of PDMS-made wells. A micropipette was used for the precise dispensing of DNA and RNA solutions. (b) An FTIR microscope system for data collection. The SEIRA sensor chip is placed on the sample stage.





**Fig. 2** Experimental workflow. (a) Measurement was performed on a clean SEIRA sensor (zoom-in view). Dashed square is a design unit cell of the SEIRA structure. (b) Step I: Complementary ssDNA (with thiol group modification) solution was immobilized onto the SEIRA substrate. Measurement was performed on the SEIRA-DNA substrate. (c) The total RNA solution containing target miRNA molecules was immobilized onto the SEIRA-DNA substrate. Measurement was performed on the SEIRA-DNA-miRNA substrate.

50  $\mu\text{M}$ ) were immobilized to the SEIRA substrate (Fig. 2(b)). The thiol group will react to Au, so the ssDNA molecules will bind to the SEIRA substrate. After 1 hour, the substrate was rinsed thoroughly with RNase-free water to remove the excess unbound ssDNA molecules. Thirdly, solutions containing target miRNA molecules (2  $\mu\text{L}$ ) extracted from breast cancer patients' serums were immobilized on the SEIRA-DNA substrate. Only target miRNA molecules will bind to the ss-DNA molecules because of the peptide bonds. After 1 hour, the sensor was rinsed thoroughly with RNase-free water to remove the excess unbound miRNA molecules. The specificity of this two-step binding process was previously studied for similar devices in our earlier papers.<sup>25–27</sup> FTIR microscope measurements were taken at each step, *i.e.*, SEIRA, SEIRA-DNA, and SEIRA-DNA-miRNA. The same workflow was applied to each well on the sensor.

### Data analysis workflow

To best quantify the change in the optical signals during the two-step binding process, a method based on calculating the area ratio under the curve of the difference spectrum was proposed, as shown in Fig. 3. Firstly, the reflectance spectrum of SEIRA ( $R_{\text{SEIRA}}(\lambda)$ ), SEIRA-DNA ( $R_{\text{SEIRA-DNA}}(\lambda)$ ), and SEIRA-DNA-miRNA ( $R_{\text{SEIRA-DNA-miRNA}}(\lambda)$ ) were measured three times at different locations. Pre-processing steps were then carried out, including baseline correction and Savitzky–Golay smoothing. Data processing steps involve firstly the calculation of the differences between the two spectra, which are eqn (1) and (2), and secondly the calculation of the area under the curves, which are eqn (3) and (4), and finally the calculation of the ratio between the two areas, which is eqn (5).

$$\Delta_{\text{DNA}}(\lambda) = R_{\text{SEIRA-DNA}}(\lambda) - R_{\text{SEIRA}}(\lambda) \quad (1)$$

$$\Delta_{\text{miRNA}}(\lambda) = R_{\text{SEIRA-DNA-miRNA}}(\lambda) - R_{\text{SEIRA-DNA}}(\lambda) \quad (2)$$

$$A_{\text{DNA}} = \int \Delta_{\text{DNA}}(\lambda) d\lambda \quad (3)$$

$$A_{\text{miRNA}} = \int \Delta_{\text{miRNA}}(\lambda) d\lambda \quad (4)$$

$$\text{Ratio} = |A_{\text{miRNA}}/A_{\text{DNA}}| \quad (5)$$

The method is termed “SEIRA-AR” in short, which stands for SEIRA Area Ratio. The ratio between the two areas under the curve represents the miRNA-DNA binding events as a percentage of the DNA-SEIRA binding events so that unsuccessful DNA binding events are not reflected. The result is a SEIRA-AR index calculated for each target miRNA type. It is worth mentioning that this index accounts for both the shift in the peak position and the change in the intensity values across the entire spectrum. Hence, it allows us to capture the total change in the optical signals due to the DNA and miRNA binding events accurately. Finally, the SEIRA-AR index values are compared with the RT-qPCR and NGS read counts for a miRNA biomarker, and a linear correlation is established to validate the method.


## Results and discussion

### Simulation results of SEIRA sensor

The SEIRA sensor design and simulation were performed using the Lumerical FDTD software (Ansys, Inc.). It was guided by the infrared absorption features of the DNA and miRNA molecules because the purpose of SEIRA is to enhance their interaction with the incident light. Hence, a first experiment was performed on a variety of synthetic thiol group-modified ssDNA and miRNA samples to obtain their infrared spectrum. As mentioned in the methodology section, this experiment was conducted using an ATR-FTIR system under a vacuum environment. The ATR accessory improves the measurement sensitivity of a conventional FTIR instrument. In addition, water has strong absorption features in the infrared region, so the vacuum condition is necessary to remove the interference from water. We have measured five types of synthetic thiolated







**Fig. 3** Data analysis workflow. Reflectance measurements of (a) SEIRA, (b) SEIRA-DNA, and (c) SEIRA-DNA-miRNA sensor surfaces. Pre-processing steps include baseline correction and Savitzky–Golay smoothing. Data processing steps include calculating the difference in spectra, the area under the curve, and the ratio between areas. The output includes the correlation between optical measurements, RT-qPCR, and NGS read counts of target miRNA molecules.

ssDNA and miRNA solution samples under vacuum and atmospheric conditions. The results are provided in Fig. S1 and S2 in the ESI.† We note that the absorption peaks, *i.e.*, the molecular fingerprints of the ss-DNAs and miRNAs could be visualized only under the vacuum condition. Selected spectra of the synthetic hsa-DNA-let-7a-5p and hsa-miR-let-7a-5p were

shown in Fig. 4(a) as the orange and green curves, respectively. The identified fingerprints are shown in Table 1, where each fingerprint is represented by a peak in the spectrum corresponding to a type of molecular vibration or chemical bond.<sup>28–31</sup> It was found that although there are slight variations in the spectra of different kinds of DNA and miRNA





**Fig. 4** SEIRA sensor design, simulation, and fabrication. (a) The reflectance of the SEIRA sensor (blue), synthetic DNA (orange), and miRNA (green) samples. (b) A schematic showing the infrared interaction and the SEIRA structures (side view). (c) A detailed schematic of the unit cell of the SEIRA structures showing the design parameters. (d) An SEM image of the fabricated SEIRA structures. (e) The electric field intensity distribution of the SEIRA structures at 1379  $\text{cm}^{-1}$ . (f) The electric field intensity distribution of the SEIRA structures at 3281  $\text{cm}^{-1}$ .

samples, there exist two prominent fingerprint regions, 800–2000  $\text{cm}^{-1}$  and 2800–3500  $\text{cm}^{-1}$ . Hence, SEIRA nanostructures with broadband multi-resonances that match these two fingerprint regions are ideal. A metallic nanorod structure

was applied and optimized so that the resonance peaks coincide with the centers of the fingerprint regions. Fig. 4(b) is a schematic showing the infrared light interacting with the SEIRA structures that consist of a  $\text{CaF}_2$  substrate and gold (Au)



**Table 1** Infrared molecular fingerprints of ssDNA and miRNA samples

Peak (cm <sup>-1</sup> )	Chemical bond
788	Free cytosine vibration
798	Free adenine vibration
813, 866	Main N-type sugar marker
915	Ribose ring vibration
966	C-C and C-O ribose stretching
995	Ribose-phosphate main chain vibration
1082	PO <sub>2</sub> <sup>-</sup> symmetric stretching
1110	C-O ribose ring stretching
1240	PO <sub>2</sub> <sup>-</sup> anti-symmetric stretching
1475	Adenine and guanine ring vibration
1492	Cytosine in-plane vibration
1600	C=N ring vibration of guanine
1650	C2=O2 stretching in cytosine
1685	C2=O2 stretching in guanine
2950	C-H stretching
3140, 3210	O-H stretching
3330, 3340	N-H stretching

nanorods. Fig. 4(c) is a schematic of the unit cell of the SEIRA structure with a long and wide nanorod and a short and narrow nanorod. The unit cell repeats in a period  $P = 3 \mu\text{m}$ . The spacing between the two nanorods is  $2D = 1.5 \mu\text{m}$ . The length, width, and height of the long and wide nanorod are:  $L_1 = 2.6 \mu\text{m}$ ,  $W_1 = 0.4 \mu\text{m}$ ,  $H_1 = H = 0.1 \mu\text{m}$ . The length, width, and height of the short and narrow nanorod are:  $L_2 = 0.85 \mu\text{m}$ ,  $W_2 = 0.08 \mu\text{m}$ ,  $H_2 = H = 0.1 \mu\text{m}$ . Fig. 4(d) is a scanning electron microscope (SEM) image of the fabricated structures. Fig. 4(e) and (f) show the electric field intensity distributions of the SEIRA structures at the two resonance peaks at  $1379 \text{ cm}^{-1}$  and  $3281 \text{ cm}^{-1}$ , respectively. Specifically, the long nanorod has a resonance at  $1379 \text{ cm}^{-1}$  with an intensity enhancement of  $1.4 \times 10^3$  times at the edges of the rod. The short nanorod has a resonance at  $3281 \text{ cm}^{-1}$  with an intensity enhancement of more than  $8 \times 10^3$  times at the edges of the rod. The resonance peak and width can be tuned by changing the length, width, and height of the nanorods. For example, an increase in the width will increase the wavenumber of the resonance peak and width. We have performed extensive optimization of the SEIRA structures using Lumerical software simulations. The optimized parameters are shown in Fig. 4(c). To determine the optimal shape and size of the Au nanorods, we selectively presented the optimization results for  $W_2$  and  $h$  variations in Fig. S3.† The selection criteria included maximizing the overlapping between the SEIRA spectrum peak wavenumbers and the DNA and miRNA reflectance peak wavenumber ranges, *i.e.*, around  $1379 \text{ cm}^{-1}$  and  $3281 \text{ cm}^{-1}$ ; maximizing the reflectance intensity of the SEIRA spectrum peaks; and maximizing the bandwidth of the SEIRA spectrum so all DNA and miRNA peaks could be enhanced. The final optimized result of the SEIRA structure is shown as the blue curve in Fig. 4(a).

### Experimental results of SEIRA enhancement

Fig. 5 shows a representative measurement result of a bare substrate area without SEIRA structures and an area with SEIRA structures. The reflectance with SEIRA was enhanced 20 times compared to a bare area. The biological reaction after



**Fig. 5** SEIRA enhancement. Reflectance measurements of a bare area without SEIRA, shown as black, an area with SEIRA structures when it was clean (red), after DNA binding (blue), and after miRNA binding (green).

each step, SEIRA, SEIRA-DNA, and SEIRA-DNA-miRNA was clearly captured in the optical measurements, which involves changes in the reflectance spectrum over the entire wavenumber range, not only a shift in the peak position.

### Experimental validation of SEIRA-AR index

Firstly, the SEIRA-AR analysis method was compared with industry standards. In our previous studies, hsa-miR-let-7a-5p (5'-UGAGGUAGUAGGUUGUAUAGUU-3') was detected through RT-qPCR and NGS methods, and a good correlation was observed between these detection methods.<sup>22,23</sup> For the SEIRA sensor experiment, the complementary ssDNA with thiol group modification was 5'-AACTATACAACCTACTACCTCA/3ThioMC3-D/-3'. Five patients (three cancerous and two non-cancerous) were measured. Their hsa-miR-let-7a-5p SEIRA-AR index values were calculated and plotted against the RT-qPCR and NGS read counts, as shown in Fig. 6(a) and (b), respectively. The mean values and the standard deviations were shown in blue circles and error bars. A linear curve fitting was performed with an equation  $y = a \times x$ , with  $a$  being the fitting parameter. The constraint that the curve intercepts at the origin reflects the physical meaning that when the read count is zero, the SEIRA-AR index value should be zero. The fitting parameters are shown in the top left corner with  $a = 6.60 \times 10^{-5}$  for RT-qPCR and  $a = 5.10 \times 10^{-5}$  for NGS.

Pearson's  $r$ , also known as Pearson's correlation coefficient, measures the strength of the linear relationship. A value closer to 1 indicates a strong positive linear correlation between the paired data.  $R$  Squared value, also known as the coefficient of determination, measures the quality of the linear relationship. A value closer to 1 indicates a better-fitted line that explains the variability of the response variable. It is seen that Pearson's  $r$  and  $R$  Squared values are 0.90 and 0.81 in both





Fig. 6 SEIRA-AR measurements of hsa-miR-let-7a-5p correlation with (a) RT-qPCR and (b) NGS results. The mean and standard deviation values are in blue, and the fitted line is in black. The curve fitting parameters, including the fitting equation, Pearson's  $r$  value, and  $R$  Squared values, are shown in the top left corner.

cases, indicating that there exists a good correlation between SEIRA-AR index values and RT-qPCR and NGS read counts. The error bars appear larger for the data at lower miRNA read counts, indicating a potential limitation of the sensor at low concentrations. This could be due to the reduced sensitivity of the sensor at low miRNA concentrations, which could result in higher measurement variability. While we have attempted to optimize the sensor design and data analysis methods to mitigate this effect, future studies may explore more complex structures to improve the accuracy and sensitivity of the sensor at low miRNA concentrations, for example, using a tetrahedral DNA nanostructure.<sup>16</sup> Nonetheless, we believe that our findings demonstrate the potential of the sensor as a sensitive and accurate platform for miRNA biomarker detection.

#### SEIRA measurements of three breast cancer biomarkers

Next, established breast cancer miRNA biomarkers were measured. An optimal six-miRNA panel was reported for differentiating malignant and benign breast cancer samples based on a study of 638 patients with abnormal mammograms and

100 healthy controls.<sup>22</sup> Here, three miRNAs from the panel were selected for detection, namely, hsa-miR-451a (5'-AAACCGUUACCAUACUGAGUU-3'), hsa-miR-126-5p (5'-CAUUAUUACUUUUGGUACGCG-3'), and hsa-miR-195-5p (5'-UAGCAGCAGAGAAUUAUUGGC-3'). The corresponding ssDNA capturing molecules with thiol group modifications were 5'-TTTGGAATGGTAATGACTCAA/3ThioMC3-D/-3', 5'-GTAATAATGTTTC-CATGCGC/3ThioMC3-D/-3', 5'-ATCGTCGTGTCTTTATAACCG/3ThioMC3-D/-3', respectively. There were five patients (four cancerous and one non-cancerous) measured. The SEIRA-AR index values obtained were plotted against known RT-qPCR read counts, as shown in Fig. 7. A linear correlation was established for each miRNA biomarker, *i.e.*,  $y = 1.36 \times 10^{-6}x$  (for hsa-miR-451a),  $y = 2.47 \times 10^{-4}x$  (for hsa-miR-126-5p), and  $y = 1.00 \times 10^{-2}x$  (for hsa-miR-195-5p). The Pearson's  $r$  values are 0.99, 0.94, 0.93, and  $R$  Squared values are 0.98, 0.88, 0.86, which indicate strong correlations. This shows that the SEIRA sensor and the SEIRA-AR analysis method are capable of multiplexed measuring of biomarker molecules of clinical samples accurately. To improve the accuracy and reliability of the linear



Fig. 7 SEIRA-AR index values correlation with RT-qPCR data for (a) hsa-miR-451a, (b) hsa-miR-126-5p, and (c) hsa-miR-195-5p. The data points in blue show the mean and standard deviation values. The linear curve fitting is represented in black. The fitting equation, Pearson's  $r$ , and  $R$  Squared values are indicated in the top left corner.





relationship between the new index value and the industry standards, future studies may consider increasing the sample size by reliable sensor platform for miRNA biomarker detection.

## Conclusions

This paper presents a multi-well SEIRA sensor chip capable of label-free, multiplexed sensing of DNA and RNA molecules based on their infrared absorption molecular fingerprints. The broadband multi-resonant SEIRA structures were designed to match the resonances with the absorption peaks of the target molecules, ensuring maximum light-matter interaction at the SEIRA/molecule interface. Simulations showed that the resonance enhancement was on the order of  $10^3$  times. The sensor can measure multiple biomarkers and samples on a single platform. We also developed a new parameter, the SEIRA-AR index, to measure specific target miRNA biomarkers in a patient's serum solution containing a mixture of RNAs, using complementary ssDNA with thiol group modifications as capturing molecules. We proposed using the ratio of the change in the area under the curve of the SEIRA spectra at each binding step as a reflection of the concentration of the target miRNA biomarker in the sample. The SEIRA-AR index values were compared with RT-qPCR and NGS read counts collecting additional data points. This could be achieved by increasing the number of measurements per well or increasing the number of samples per biomarker. The larger sample size would enable a more comprehensive evaluation of the sensor's performance and improve the statistical significance of the results. However, we recognize that increasing the sample size may require additional resources and time, and thus it may not be feasible in all cases. Nonetheless, we believe that this is an important direction for future research in developing a robust and for breast cancer biomarkers using clinical samples. An excellent correlation was established, with a Pearson's  $r$  value up to 0.99 and an  $R$  Squared value up to 0.98 for detecting hsa-miR-let-7a-5p, hsa-miR-451a, hsa-miR-126-5p, and hsa-miR-195-5p. Compared to RT-qPCR and NGS methods, the proposed SEIRA sensor offers significant advantages: it is label-free, relatively fast (less than 2 hours), and cost-effective. In summary, we have demonstrated, for the first time, the use of a SEIRA sensor on clinical breast cancer samples for miRNA biomarker detection, and developed an analysis method that produces results that can be benchmarked with industry standards. The sensor and analysis approach could also be applied to other biomarker detection and biosensing activities that involve the use of a complementary molecule as the capturing agent. An area for improvement of the current device is to increase detection speed, such as developing a read-out system to capture spectral information at all detection sites simultaneously. With necessary refinement and optimization, we envision that this sensor can be used for routine medical diagnosis in the future.

## Author contributions

Conception: S. Zhang, D. C. L. Wong, A. S. G. Lee, J. Teng, D. U. S., and M. Olivo. Simulation: S. Zhang and D. C. L. Wong. Clinical samples: M. Hum, E. Y. Tan, and A. S. G. Lee. Experiment: S. Zhang, Q. Y. S. Wu, and Y. F. Chen, Manuscript preparation: S. Zhang, Q. Y. S. Wu, Y. F. Chen, M. Hum, and D. U. S. Supervision: A. S. G. Lee, J. Teng, D. U. S., and M. Olivo.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

The authors would like to thank Jayakumar Perumal for helping with the PDMS-made wells; Ghayathri Balasundaram for insightful discussions; Grace Chong, Sahad Zamir, and Casey Ang for helping with the data collection; Valerie Teo and Sonia Tan for helping with data analysis and figure preparation. Agency for Science, Technology and Research, Singapore: IAF-PP Grant H19H6a0025 and BMRC UIBR Grant; National Medical Research Council, Singapore: NMRC/CBRG/0087/2015.

## References

- 1 M. Arnold, E. Morgan, H. Rumgay, A. Mafra, D. Singh, M. Laversanne, J. Vignat, J. R. Gralow, F. Cardoso, S. Siesling and I. Soerjomataram, *Breast*, 2000, **66**, 15–23.
- 2 H. D. Nelson, M. Pappas, A. Cantor, J. Griffin, M. Daeges and L. Humphrey, *Ann. Intern. Med.*, 2016, **164**, 256–256.
- 3 C. V. D. Ende, A. M. Oordt-Speets, H. Vroiling and H. M. E. V. Agt, *Int. J. Cancer*, 2017, **141**, 1295–1306.
- 4 H. D. Nelson, E. S. O'meara, K. Kerlikowske, S. Balch and D. Miglioretti, *Ann. Intern. Med.*, 2016, **164**, 226–226.
- 5 T. Li, J. Li, R. Heard, Z. Gandomkar, J. Ren, M. Dai and P. Brennan, *Asia. Pac. J. Clin. Oncol.*, 2022, 696–705.
- 6 M. S. Ong and K. D. Mandl, *Health Aff.*, 2015, **34**, 576–583.
- 7 S. Y. Loke and A. S. G. Lee, *Eur. J. Cancer*, 2018, **92**, 54–68.
- 8 L. Sempere, C. Graveel, H. Calderone, J. Westerhuis and M. Winn, *Breast Cancer: Targets Ther.*, 2015, **7**, 59–79.
- 9 H. M. Heneghan, N. Miller, A. J. Lowery, K. J. Sweeney and M. J. Kerin, *J. Oncol.*, 2010, 950201–950201.
- 10 T. Ouyang, Z. Liu, Z. Han and Q. Ge, *Anal. Chem.*, 2019, **91**, 3179–3186.
- 11 M. Janneh, *Results Opt.*, 2022, **6**, 100201.
- 12 F. Neubrech, C. Huck, K. Weber, A. Pucci and H. Giessen, *Chem. Rev.*, 2017, **117**, 5110–5145.
- 13 H. Aouani, M. Rahmani, H. Šípová, V. Torres, K. Hegnerová, M. Beruete, J. Homola, M. Hong, M. Navarro-Cía and S. A. Maier, *J. Phys. Chem. C*, 2013, **117**, 18620–18626.



- 14 D. Rodrigo, A. Tittl, N. Ait-Bouziad, A. John-Herpin, O. Limaj, C. Kelly, D. Yoo, N. J. Wittenberg, S. H. Oh, H. A. Lashuel and H. Altug, *Nat. Commun.*, 2018, **9**, 2160–2160.
- 15 T. D. Dao, K. Chen and T. Nagao, *Nanoscale*, 2019, **11**, 9508–9517.
- 16 X. Hui, C. Yang, D. Li, X. He, H. Huang, H. Zhou, M. Chen, C. Lee and X. Mu, *Adv. Sci.*, 2021, **8**, 2100583.
- 17 M. Zhao, J. Li, M. Sebek, L. Yang, Y. J. Liu, M. Bosman, Q. Wang, X. Zheng, J. Lu and J. Teng, *Adv. Mater.*, 2021, 2101950–2101950.
- 18 Z. Yao, Q. Zhang, W. Zhu, M. Galluzzi, W. Zhou, J. Li, A. V. Zayats and X. F. Yu, *Nanoscale*, 2021, **13**, 10133–10142.
- 19 Y. Bian, Y. Li, K. Liu, H. He, Y. Feng and X. Yu, *J. Biophotonics*, 2022, e202200277.
- 20 L. Dong, X. Yang, C. Zhang, B. Cerjan, L. Zhou, M. L. Tseng, Y. Zhang, A. Alabastri, P. Nordlander and N. J. Halas, *Nano Lett.*, 2017, **17**, 5768–5774.
- 21 S. Zhang, C. L. Wong, S. Zeng, R. Bi, K. Tai, K. Dholakia and M. Olivo, *Nanophotonics*, 2020, **10**, 259–293.
- 22 R. Zou, S. Y. Loke, V. K. Tan, S. T. Quek, P. Jagmohan, Y. C. Tang, P. Madhukumar, B. K. Tan, W. S. Yong, Y. Sim, S. Z. Lim, E. Png, S. Y. S. Lee, M. Y. P. Chan, T. S. J. Ho, B. K. J. Khoo, S. L. J. Wong, C. H. Thng, B. K. Chong, Y. Y. Teo, H. P. Too, M. Hartman, N. C. Tan, E. Y. Tan, S. C. Lee, L. Zhou and A. S. G. Lee, *Cancers*, 2021, **13**, 2130–2130.
- 23 S. Y. Loke, P. Munusamy, G. L. Koh, C. H. T. Chan, P. Madhukumar, J. L. Thung, K. T. B. Tan, K. W. Ong, W. S. Yong, Y. Sim, C. L. Oey, S. Z. Lim, M. Y. P. Chan, T. S. J. Ho, B. K. J. Khoo, S. L. J. Wong, C. H. Thng, B. K. Chong, E. Y. Tan, V. K. M. Tan and A. S. G. Lee, *Cancers*, 2019, **11**, 1872.
- 24 R. Zou, S. Y. Loke, Y. C. Tang, H. P. Too, L. Zhou, A. S. G. Lee and M. Hartman, *Br. J. Cancer*, 2022, **126**, 472–481.
- 25 C. L. Wong, S. Y. Loke, H. Q. Lim, G. Balasundaram, P. Chan, B. K. Chong, E. Y. Tan, A. S. G. Lee and M. Olivo, *J. Biophotonics*, 2021, **14**, e202100153.
- 26 K. K. Maiti, U. S. Dinish, A. Samanta, M. Vendrell, K. S. Soh, S. J. Park, M. Olivo and Y. T. Chang, *Nano Today*, 2012, **7**, 85–93.
- 27 D. U.S., C. Y. Fu, K. S. Soh, B. Ramaswamy, A. Kumar and M. Olivo, *Biosens. Bioelectron.*, 2012, **33**, 293–298.
- 28 F. Geinguenaud, V. Militello and V. Arluison, *RNA Spectroscopy Methods and Protocols*, 2020, pp. 119–133.
- 29 M. Banyay, M. Sarkar and A. Gräslund, *Biophys. Chem.*, 2003, **104**, 477–488.
- 30 M. Tsuboi, *Appl. Spectrosc. Rev.*, 1970, **3**, 45–90.
- 31 I.R. Spectrum Table & Chart. Retrieved from: <https://www.sigmaaldrich.com/SG/en/technical-documents/technical-article/analytical-chemistry/photometry-and-reflectometry/ir-spectrum-table>.

